Showing results (131-140 of 332) with videos related to
Sort By:
Pageof 34
Bulletin Du Cancer|November 29, 2017
[Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)]Nabil Yafour, Florence Beckerich, Claude Eric Bulabois, et al.Annals of Hematology|March 16, 2019
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective studySabrina Trudel, Benoît Tessoulin, Maxime Jullien, et al.Bone Marrow Transplantation|November 29, 2020
Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMTAnnalisa Paviglianiti, Myriam Labopin, Didier Blaise, et al.Journal of Clinical Immunology|July 29, 2025
Molecular Interactions Between NK Cells and Acute Leukemic Cells: KIR2DL5 Drastically Limits NK Cell ResponsesEnora Ferron, Maxime Jullien, Martin Braud, et al.British Journal of Haematology|November 9, 2018
A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patientsRobin Boutault, Pierre Peterlin, Marouane Boubaya, et al.Oncotarget|April 2, 2016
High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia - an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationTomasz Czerw, Myriam Labopin, Christoph Schmid, et al.Annals of Hematology|April 29, 2020
Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamideAlice Garnier, Thierry Guillaume, Pierre Peterlin, et al.Hematology Reports|May 28, 2024
Treatment Patterns and Clinical Outcomes of Patients with Moderate to Severe Acute Graft-Versus-Host Disease: A Multicenter Chart Review StudyDavid Michonneau, Raynier Devillier, Mikko Keränen, et al.Journal of Hematology & Oncology|May 4, 2021
Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemiaBhagirathbhai Dholaria, Myriam Labopin, Jaime Sanz, et al.Haematologica|March 10, 2022
High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALLAurelie Cabannes-Hamy, Eolia Brissot, Thibaut Leguay, et al.Pageof 34